ATE529107T1 - Ligustilid-derivate zur behandlung von entzündungserkrankungen - Google Patents
Ligustilid-derivate zur behandlung von entzündungserkrankungenInfo
- Publication number
- ATE529107T1 ATE529107T1 AT06753874T AT06753874T ATE529107T1 AT E529107 T1 ATE529107 T1 AT E529107T1 AT 06753874 T AT06753874 T AT 06753874T AT 06753874 T AT06753874 T AT 06753874T AT E529107 T1 ATE529107 T1 AT E529107T1
- Authority
- AT
- Austria
- Prior art keywords
- formula
- compounds
- treatment
- hydroxyl
- manufacture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05011203 | 2005-05-24 | ||
PCT/EP2006/005005 WO2006125651A2 (en) | 2005-05-24 | 2006-05-24 | Ligustilide derivatives for the treatment of inflammatory disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE529107T1 true ATE529107T1 (de) | 2011-11-15 |
Family
ID=37054238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06753874T ATE529107T1 (de) | 2005-05-24 | 2006-05-24 | Ligustilid-derivate zur behandlung von entzündungserkrankungen |
Country Status (8)
Country | Link |
---|---|
US (2) | US20090176873A1 (de) |
EP (1) | EP1937250B1 (de) |
JP (1) | JP2008542226A (de) |
KR (1) | KR20080015802A (de) |
CN (1) | CN101184484B (de) |
AT (1) | ATE529107T1 (de) |
ES (1) | ES2375302T3 (de) |
WO (1) | WO2006125651A2 (de) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090033470A (ko) * | 2006-07-14 | 2009-04-03 | 디에스엠 아이피 어셋츠 비.브이. | 로즈힙 및 다른 활성 약품을 포함하는, 염증성 질환의 치료를 위한 조성물 |
WO2008006582A1 (en) * | 2006-07-14 | 2008-01-17 | Dsm Ip Assets B.V. | Compositions comprising magnolol or honokiol and other active agents for the treatment of inflammatory diseases |
EP2040696B1 (de) * | 2006-07-14 | 2017-01-25 | DSM IP Assets B.V. | Zubereitungen und deren verwendung für die behandlung, begleitende behandlung oder vorbeugung entzündlicher zuständen |
CN101991568B (zh) * | 2009-08-12 | 2012-02-08 | 上海张江中药现代制剂技术工程研究中心 | 洋川芎内酯i在制备抗抑郁症药物、偏头痛药物及其他5-羟色胺能系统相关疾病药物中的应用 |
CN102844027A (zh) * | 2009-11-23 | 2012-12-26 | 培力(香港)健康产品有限公司 | 治疗炎症和免疫系统障碍的新治疗方法 |
CN106074497A (zh) * | 2010-01-13 | 2016-11-09 | 石药集团恩必普药业有限公司 | 丁苯酞及其衍生物在制备治疗帕金森病的药物中的应用 |
US8927601B2 (en) * | 2011-12-20 | 2015-01-06 | National Dong Hwa University | Uses of N-butylidenephthalide in treating a liver injury and improving liver function |
TWI460168B (zh) * | 2012-08-10 | 2014-11-11 | Univ China Medical | 用於抑制運動神經元自體吞噬之醫藥組合物及其應用 |
BR112015001989B1 (pt) * | 2012-08-17 | 2022-06-14 | China Medical University | Uso de butilidenoftalida (bp) |
CN102793696B (zh) * | 2012-08-31 | 2014-09-10 | 甘肃中医学院 | 丁苯酞在制备治疗支气管哮喘药物中的应用 |
TWI487521B (zh) * | 2013-03-12 | 2015-06-11 | Hawking Biolog Technology Co Ltd | 苯酞化合物之應用 |
US20140271568A1 (en) | 2013-03-12 | 2014-09-18 | Hawking Biological Technology Co., Ltd | Method and kit for providing an increased expression of telomerase, brain-derived neurotrophic factor, stromal cell-derived factor-1, cxc chemokine receptor 4, and/or immune regulatory factor of stem cell |
TWI511727B (zh) | 2014-07-02 | 2015-12-11 | Everfront Biotech Inc | 苯酞化合物之應用 |
EP3175851B1 (de) * | 2014-07-28 | 2021-08-18 | Everfront Biotech Inc. | Verwendung von butenylphthalid, verwendungsverfahren dafür und verfahren zur zubereitung davon in eine pharmazeutische zusammensetzung |
CN105311014A (zh) * | 2014-07-28 | 2016-02-10 | 李德财 | 丁烯基苯酞的用途及将其制备为医药组合物的方法 |
WO2016037587A1 (en) * | 2014-09-11 | 2016-03-17 | Taiwan Mitochondrion Applied Technology Co., Ltd | Pharmaceutical compositions for treating degenerative neurological disease with mitocells |
JP6718522B2 (ja) * | 2016-05-19 | 2020-07-08 | 長弘生物科技股▲ふん▼有限公司 | 肺線維症の発症および/または治療の遅延のための医薬製剤 |
US10688128B2 (en) * | 2016-05-23 | 2020-06-23 | Everfront Biotech Inc. | Use of Z-butylidenephthalide in activating autoimmune system |
CN106432161A (zh) * | 2016-07-19 | 2017-02-22 | 四川大学 | 一类3‑烃基‑5,6‑二氧取代苯酞化合物及其制备方法和用途 |
CN107669689B (zh) * | 2017-11-07 | 2021-04-30 | 浙江大学 | 一种治疗慢性阻塞性肺病的气雾剂 |
CN109350620B (zh) * | 2018-12-15 | 2019-08-06 | 谭志军 | 一种治疗卵巢癌的药物及其用途 |
CN109498617A (zh) * | 2018-12-26 | 2019-03-22 | 南京中医药大学 | 藁本内酯在制备防治骨质疏松症药品中的应用 |
CN111617071B (zh) * | 2019-02-27 | 2023-05-23 | 苏州凯祥生物科技有限公司 | 一种高尿酸血症药物组合物及用于治疗高尿酸血症的药物 |
CN109966288A (zh) * | 2019-05-05 | 2019-07-05 | 嘉兴市第二医院 | 一种治疗或预防动脉粥样硬化药物及应用 |
CN110169965B (zh) * | 2019-05-28 | 2021-10-08 | 江苏康缘药业股份有限公司 | 一种化合物在治疗软骨退变性疾病方面的应用 |
CN114209691A (zh) * | 2022-01-06 | 2022-03-22 | 正大青春宝药业有限公司 | 一种洋川芎内酯i复合物及在治疗心肌肥大疾病中的应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01199958A (ja) * | 1987-07-23 | 1989-08-11 | Tsumura & Co | 新規なフタリド誘導体およびその製造方法 |
JPS6450818A (en) * | 1987-08-20 | 1989-02-27 | Tsumura & Co | Prostaglandin f2alpha-inhibitor |
JPH01207233A (ja) * | 1988-02-12 | 1989-08-21 | Tsumura & Co | 抗動脈硬化症剤 |
JPH0477480A (ja) * | 1990-07-19 | 1992-03-11 | Tsumura & Co | フタリド誘導体 |
EP0500233A2 (de) | 1991-02-14 | 1992-08-26 | National Semiconductor Corporation | Bipolartransistorstruktur und BICMOS IC-Herstellungsverfahren |
WO1995000157A1 (en) * | 1993-06-25 | 1995-01-05 | Mobius Consultancy Pty. Ltd. | Therapeutic agent |
ATE362468T1 (de) * | 2000-07-25 | 2007-06-15 | Merck & Co Inc | N-substituierte indole mit anwendung in der behandlung von diabetes |
US6407250B1 (en) * | 2000-09-14 | 2002-06-18 | Allergan Sales, Inc. | Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists |
ES2327639T3 (es) * | 2003-05-14 | 2009-11-02 | Dsm Ip Assets B.V. | Uso de derivados de ftalida para el tratamiento y prevecion de diabetes mellitus. |
CN1569848A (zh) * | 2003-07-14 | 2005-01-26 | 中国中医研究院中药研究所 | 治疗缺血性心脏病的川芎内酯及其制备方法 |
CN1302775C (zh) * | 2003-11-25 | 2007-03-07 | 中国人民解放军第二军医大学 | 藁本内酯用于防治动脉粥样硬化的用途 |
-
2006
- 2006-05-24 ES ES06753874T patent/ES2375302T3/es active Active
- 2006-05-24 EP EP06753874A patent/EP1937250B1/de not_active Not-in-force
- 2006-05-24 CN CN2006800182412A patent/CN101184484B/zh not_active Expired - Fee Related
- 2006-05-24 KR KR1020077027212A patent/KR20080015802A/ko not_active Application Discontinuation
- 2006-05-24 US US11/920,346 patent/US20090176873A1/en not_active Abandoned
- 2006-05-24 AT AT06753874T patent/ATE529107T1/de not_active IP Right Cessation
- 2006-05-24 WO PCT/EP2006/005005 patent/WO2006125651A2/en active Application Filing
- 2006-05-24 JP JP2008512773A patent/JP2008542226A/ja not_active Withdrawn
-
2010
- 2010-06-18 US US12/801,646 patent/US20100298427A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1937250B1 (de) | 2011-10-19 |
US20090176873A1 (en) | 2009-07-09 |
CN101184484A (zh) | 2008-05-21 |
KR20080015802A (ko) | 2008-02-20 |
US20100298427A1 (en) | 2010-11-25 |
WO2006125651A3 (en) | 2007-07-19 |
ES2375302T3 (es) | 2012-02-28 |
EP1937250A2 (de) | 2008-07-02 |
CN101184484B (zh) | 2011-10-05 |
JP2008542226A (ja) | 2008-11-27 |
WO2006125651A2 (en) | 2006-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE529107T1 (de) | Ligustilid-derivate zur behandlung von entzündungserkrankungen | |
MX2007013065A (es) | Derivados de dihidrobenzofurano y usos de los mismos. | |
DK1765816T3 (da) | Substituerede 1-propinylpiperaziner med affinitet for MGluR5-receptoren til behandling af smertetilstande | |
IS8502A (is) | Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar | |
EA200602062A1 (ru) | Амидосоединения и их применение в качестве фармацевтических средств | |
SE0403006D0 (sv) | New compounds | |
WO2006044362A3 (en) | N-sulfonylpiperidine cannabinoid receptor 1 antagonists | |
MA28279A1 (fr) | Derives d'indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2 | |
ATE435210T1 (de) | Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten | |
IS8503A (is) | Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar | |
WO2004013120A8 (en) | Novel benzodioxoles | |
DE602005008558D1 (de) | Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen reznkungen | |
DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
ATE413388T1 (de) | Muskarin antagonisten | |
ES2311803T3 (es) | Composiciones embolicas de silicie pirogena. | |
DE602004012858D1 (de) | 2-aminobenzothiazole als cb1 rezeptor inverse agonisten | |
UA83917C2 (en) | 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors | |
NO20064238L (no) | Imidazolinderivater med CB1 agonistlsk aktivitet | |
ATE384058T1 (de) | Thiazolderivate | |
ATE432278T1 (de) | Verbindungen zur behandlung von krankheiten | |
ATE491446T1 (de) | Ligustilid zur behandlung von erkrankungen des zentralen nervensystems | |
DE602006010738D1 (de) | Pyrroloä2,3-cüpyridinderivate | |
BRPI0516602A (pt) | composto, e, composição farmacêutica | |
BR0308184A (pt) | Composição oftálmica compreendendo ascomicina | |
BR0105787A (pt) | Composição farmacêutica, uso de um composto farmacêutico, método para tratamento de distúrbios, composto farmacêutico e método para confeccionar um composto farmacêutico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |